Rajiv Janardhanan1, Binxia Yang1, Sreenivasulu Kilari1, Edward B Leof2, Debabrata Mukhopadhyay2, Sanjay Misra3. 1. Amity Institute of Public Health, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India; Vascular and Interventional Radiology Translational Laboratory Mayo Clinic, 200 First Street SW, Rochester, MN 55905. 2. Department of Radiology, and Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. 3. Amity Institute of Public Health, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India; Vascular and Interventional Radiology Translational Laboratory Mayo Clinic, 200 First Street SW, Rochester, MN 55905; Department of Radiology, and Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. Electronic address: misra.sanjay@mayo.edu.
Abstract
PURPOSE: To determine if a second dose of a lentivirus mediated small hairpin RNA that inhibits Vegf-A gene expression (LV-shRNA-Vegf-A) can improve lumen vessel area (LVA) of the outflow vein of an arteriovenous fistula (AVF) and decrease venous neointimal hyperplasia. MATERIALS AND METHODS: Chronic kidney disease was created in C57BL/6 mice; 28 days later, an AVF was created by connecting the right carotid artery to the ipsilateral jugular vein. Immediately after AVF creation, 5 × 10(6) plaque-forming units of LV-shRNA-Vegf-A or control shRNA was administered to the adventitia of the outflow vein, and a second dose of the same treatment was administered 14 days later. Animals were sacrificed at 21 days, 28 days, and 42 days after AVF creation for reverse transcription polymerase chain reaction and histomorphometric analyses. RESULTS: By day 21, there was a 125% increase in the average LVA (day 21, P = .11), with a decrease in cell proliferation (day 21, P = .0079; day 28, P = .28; day 42, P = .5), decrease in α-smooth muscle cell actin staining (day 21, P < .0001; day 28, P < .05; day 42, P = .59), and decrease in hypoxic stress (day 21, P < .001; day 28, P = .28; day 42, P = .46) in LV versus control shRNA vessels. CONCLUSIONS: A second dose of LV-shRNA-Vegf-A administration results in a moderate improvement in LVA at day 21.
PURPOSE: To determine if a second dose of a lentivirus mediated small hairpin RNA that inhibits Vegf-A gene expression (LV-shRNA-Vegf-A) can improve lumen vessel area (LVA) of the outflow vein of an arteriovenous fistula (AVF) and decrease venous neointimal hyperplasia. MATERIALS AND METHODS:Chronic kidney disease was created in C57BL/6 mice; 28 days later, an AVF was created by connecting the right carotid artery to the ipsilateral jugular vein. Immediately after AVF creation, 5 × 10(6) plaque-forming units of LV-shRNA-Vegf-A or control shRNA was administered to the adventitia of the outflow vein, and a second dose of the same treatment was administered 14 days later. Animals were sacrificed at 21 days, 28 days, and 42 days after AVF creation for reverse transcription polymerase chain reaction and histomorphometric analyses. RESULTS: By day 21, there was a 125% increase in the average LVA (day 21, P = .11), with a decrease in cell proliferation (day 21, P = .0079; day 28, P = .28; day 42, P = .5), decrease in α-smooth muscle cell actin staining (day 21, P < .0001; day 28, P < .05; day 42, P = .59), and decrease in hypoxic stress (day 21, P < .001; day 28, P = .28; day 42, P = .46) in LV versus control shRNA vessels. CONCLUSIONS: A second dose of LV-shRNA-Vegf-A administration results in a moderate improvement in LVA at day 21.
Authors: P P G M Rooijens; J H M Tordoir; T Stijnen; J P J Burgmans; A A E A Smet de; T I Yo Journal: Eur J Vasc Endovasc Surg Date: 2004-12 Impact factor: 7.069
Authors: Sanjay Misra; Michael G Doherty; David Woodrum; Jay Homburger; Jaywant N Mandrekar; Stephane Elkouri; Enrique A Sabater; Haraldur Bjarnason; Alex A Fu; James F Glockner; Eddie L Greene; Debabrata Mukhopadhyay Journal: Kidney Int Date: 2005-12 Impact factor: 10.612
Authors: Rohit Khurana; Zhenwu Zhuang; Shalini Bhardwaj; Masahiro Murakami; Ebo De Muinck; Seppo Yla-Herttuala; Napoleone Ferrara; John F Martin; Ian Zachary; Michael Simons Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Li Li; Christi M Terry; Donald K Blumenthal; Tadashi Kuji; Takahisa Masaki; Bonnie C H Kwan; Ilya Zhuplatov; John K Leypoldt; Alfred K Cheung Journal: Nephrol Dial Transplant Date: 2007-06-30 Impact factor: 5.992
Authors: Sanjay Misra; Alex A Fu; Alessandra Puggioni; Kamran M Karimi; Jaywant N Mandrekar; James F Glockner; Luis A Juncos; Bilal Anwer; Antonio M McGuire; Debabrata Mukhopadhyay Journal: Am J Physiol Heart Circ Physiol Date: 2008-03-07 Impact factor: 4.733
Authors: H P Gerber; K J Hillan; A M Ryan; J Kowalski; G A Keller; L Rangell; B D Wright; F Radtke; M Aguet; N Ferrara Journal: Development Date: 1999-03 Impact factor: 6.868
Authors: Chenglei Zhao; Sean T Zuckerman; Chuanqi Cai; Sreenivasulu Kilari; Avishek Singh; Michael Simeon; Horst A von Recum; Julius N Korley; Sanjay Misra Journal: J Am Heart Assoc Date: 2020-12-05 Impact factor: 5.501